
RCPIQ
US listing · $153,400 market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2016
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 22, 2023 | Time not confirmed | — | 0.00 | — |
| Nov 9, 2022 | Time not confirmed | — | 0.00 | — |
| Aug 11, 2022 | Time not confirmed | — | 0.00 | — |
| May 17, 2022 | Time not confirmed | — | 0.00 | — |
| Mar 23, 2022 | Time not confirmed | — | 0.00 | — |
| Nov 10, 2021 | Time not confirmed | — | 0.00 | — |
| Aug 12, 2021 | Time not confirmed | — | 0.00 | — |
| May 18, 2021 | Time not confirmed | — | 0.00 | — |
| Mar 24, 2021 | Time not confirmed | — | 0.00 | — |
| Nov 11, 2020 | Time not confirmed | — | 0.00 | — |
| Aug 13, 2020 | Time not confirmed | — | 0.00 | — |
| May 19, 2020 | Time not confirmed | — | 0.00 | — |
| Mar 25, 2020 | Time not confirmed | — | 0.00 | — |
Rock Creek Pharmaceuticals, Inc., a pharmaceutical development company, focuses on the discovery, development, and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its lead compound is Anatabine citrate, a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics, with a mechanism of action distinct from other anti-inflammatory…
| Time not confirmed |
| — |
| 0.00 |
| — |
| Aug 8, 2019 | Time not confirmed | — | 0.00 | — |
| May 14, 2019 | Time not confirmed | — | 0.00 | — |
| Mar 27, 2019 | Time not confirmed | — | 0.00 | — |
| Nov 7, 2018 | Time not confirmed | — | 0.00 | — |
| Aug 9, 2018 | Time not confirmed | — | 0.00 | — |
| May 15, 2018 | Time not confirmed | — | 0.00 | — |
| Mar 21, 2018 | Time not confirmed | — | 0.00 | — |